2016: KEI comments on NIH proposal for exclusive licenses to Dimension Therapeutics, Inc.
On May 24th, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dimension Therapeutics, Inc. for the development of an Adeno-Associated Virus Vectors for the Treatment of Glycogen… Continue Reading